{"id":43589,"date":"2026-02-14T17:43:08","date_gmt":"2026-02-14T17:43:08","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/head-and-neck-cancer-therapeutics-market-mordor\/"},"modified":"2026-09-25T03:17:57","modified_gmt":"2026-09-24T18:17:57","slug":"head-and-neck-cancer-therapeutics-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/head-and-neck-cancer-therapeutics-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \ub450\uacbd\ubd80\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026\ub144 &#8211; 2031\ub144)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/head-and-neck-cancer-therapeutics-market_1668597936083_Picture1.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/head-and-neck-cancer-therapeutics-market-size-image-1768490293197.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">\n    1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">\n          1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          1.2 \uc5f0\uad6c \ubc94\uc704<\/p>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">\n    2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">\n    3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">\n    4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">\n          4.1 \uc2dc\uc7a5 \uac1c\uc694<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          4.2 \uc2dc\uc7a5 \ub3d9\uc778<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          4.2.1 HPV \uc591\uc131 \uad6c\uc778\ub450\uc554 \ubc1c\ubcd1\ub960 \uc99d\uac00<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.2 1\ucc28 PD-1\/PD-L1 \uba74\uc5ed\uc694\ubc95\uc73c\ub85c\uc758 \uc804\ud658<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.3 \ud655\ub300\ub418\ub294 \ubcf4\ud5d8 \uc801\uc6a9 \ubc0f \uac00\uc774\ub4dc\ub77c\uc778 \ud3ec\ud568<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.4 EGFR \ud45c\uc801 \ubcf5\ud569 \uc694\ubc95\uc758 \ucc44\ud0dd \uc99d\uac00<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.5 \uc870\uae30 \uc9c4\ub2e8\uc744 \uc704\ud55c AI \uae30\ubc18 \uc774\ube44\uc778\ud6c4\uacfc \uc601\uc0c1 (\uacfc\uc18c \ubcf4\uace0\ub428)<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.2.6 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed \uc131\uc778 \ub0a8\uc131 HPV \ub530\ub77c\uc7a1\uae30 \ud504\ub85c\uadf8\ub7a8 (\uacfc\uc18c \ubcf4\uace0\ub428)<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          4.3 \uc2dc\uc7a5 \uc81c\uc57d<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          4.3.1 IO \ubc0f \ud45c\uc801 \uc57d\ubb3c\uc758 \ub192\uc740 \ube44\uc6a9<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.3.2 \uc2ec\uac01\ud55c \uce58\ub8cc \uad00\ub828 \ub3c5\uc131<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.3.3 \uc81c\ud55c\ub41c \ubc14\uc774\uc624\ub9c8\ucee4 \uac80\uc0ac \uc778\ud504\ub77c<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.3.4 \ube60\ub978 FGFR \ub0b4\uc131\uc744 \uc720\ubc1c\ud558\ub294 \uc885\uc591 \uc720\uc804\uc801 \uc774\uc9c8\uc131 (\uacfc\uc18c \ubcf4\uace0\ub428)<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          4.4 \uac00\uce58 \/ \uacf5\uae09\ub9dd \ubd84\uc11d<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          4.5 \uaddc\uc81c \ud658\uacbd<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          4.6 \uae30\uc220 \uc804\ub9dd<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          4.7 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          4.7.1 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.7.2 \uacf5\uae09\uc790\uc758 \uad50\uc12d\ub825<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.7.3 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.7.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          4.7.5 \uc0b0\uc5c5 \ub0b4 \uacbd\uc7c1<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">\n    5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (\uac00\uce58)<\/p>\n<ul>\n<li class=\"toc-level-2\">\n          5.1 \uc57d\ubb3c \uc885\ub958\ubcc4<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          5.1.1 PD-1\/PD-L1 \uc5b5\uc81c\uc81c<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.1.2 EGFR \uc5b5\uc81c\uc81c<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.1.3 VEGF\/\ud608\uad00\uc2e0\uc0dd \uc5b5\uc81c\uc81c<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.1.4 \ub2e4\uc911 \ud0a4\ub098\uc544\uc81c \uc5b5\uc81c\uc81c<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.1.5 \uae30\ud0c0<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          5.2 \uc801\uc751\uc99d\ubcc4<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          5.2.1 \uad6c\uac15\uc554<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.2.2 \uad6c\uc778\ub450\uc554<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.2.3 \ube44\uc778\ub450\uc554<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.2.4 \ud6c4\ub450\uc554 &amp; \ud558\uc778\ub450\uc554<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.2.5 \uce68\uc0d8 &amp; \uae30\ud0c0<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          5.3 \ud22c\uc5ec \uacbd\ub85c\ubcc4<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          5.3.1 \uc815\ub9e5 \uc8fc\uc0ac<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.3.2 \uacbd\uad6c<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.3.3 \uae30\ud0c0<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          5.4 \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          5.4.1 \ubcd1\uc6d0<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.4.2 \uc804\ubb38 \uc554 \uc13c\ud130<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.4.3 \uc18c\ub9e4 &amp; \uc628\ub77c\uc778 \uc57d\uad6d<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">\n          5.5 \uc9c0\uc5ed\ubcc4<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          5.5.1 \ubd81\ubbf8<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.1.1 \ubbf8\uad6d<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.1.2 \uce90\ub098\ub2e4<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.1.3 \uba55\uc2dc\ucf54<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.5.2 \uc720\ub7fd<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.2.1 \ub3c5\uc77c<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.2.2 \uc601\uad6d<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.2.3 \ud504\ub791\uc2a4<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.2.4 \uc774\ud0c8\ub9ac\uc544<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.2.5 \uc2a4\ud398\uc778<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.2.6 \uc720\ub7fd \uae30\ud0c0<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.5.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.3.1 \uc911\uad6d<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.3.2 \uc778\ub3c4<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.3.3 \uc77c\ubcf8<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.3.4 \ub300\ud55c\ubbfc\uad6d<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.3.5 \ud638\uc8fc<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.3.6 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uae30\ud0c0<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.5.4 \ub0a8\ubbf8<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.4.1 \ube0c\ub77c\uc9c8<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.4.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.4.3 \ub0a8\ubbf8 \uae30\ud0c0<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          5.5.5 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.5.1 GCC<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.5.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/p>\n<\/li>\n<li class=\"toc-level-4\">\n          5.5.5.3 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74 \uae30\ud0c0<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">\n    6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">\n          6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/p>\n<\/li>\n<li class=\"toc-level-2\">\n          6.3 \uae30\uc5c5 \ud504\ub85c\ud544 (\uae00\ub85c\ubc8c \uc218\uc900 \uac1c\uc694, \uc2dc\uc7a5 \uc218\uc900 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc0ac\uc6a9 \uac00\ub2a5\ud55c \uc7ac\ubb34 \uc815\ubcf4, \uc804\ub7b5 \uc815\ubcf4, \uc8fc\uc694 \uae30\uc5c5\uc758 \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 \ubc0f \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \ud3ec\ud568)<\/p>\n<ul>\n<li class=\"toc-level-3\">\n          6.3.1 Merck &amp; Co., Inc.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.2 Bristol Myers Squibb Company<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.3 Eli Lilly and Company<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.4 AstraZeneca plc<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.5 F. Hoffmann-La Roche Ltd<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.6 Pfizer Inc.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.7 Sanofi<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.8 Regeneron Pharmaceuticals, Inc.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.9 GlaxoSmithKline plc<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.10 Johnson &amp; Johnson (Janssen Biotech)<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.11 Novartis AG<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.12 Takeda Pharmaceutical Company Limited<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.13 BeiGene Ltd.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.14 Jiangsu Hengrui Medicine Co., Ltd.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.15 Innovent Biologics, Inc.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.16 Eisai Co., Ltd.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.17 Ono Pharmaceutical Co., Ltd.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.18 CStone Pharmaceuticals Co., Ltd.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.19 Iovance Biotherapeutics, Inc.<\/p>\n<\/li>\n<li class=\"toc-level-3\">\n          6.3.20 Exelixis, Inc.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">\n    7. \uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ub450\uacbd\ubd80\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5 \uac1c\uc694<\/p>\n<p>2026\ub144 \ub450\uacbd\ubd80\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 25.4\uc5b5 \ub2ec\ub7ec \uaddc\ubaa8\ub85c \ucd94\uc815\ub418\uba70, 2025\ub144 22.7\uc5b5 \ub2ec\ub7ec\uc5d0\uc11c \uc131\uc7a5\ud558\uc5ec 2031\ub144\uc5d0\ub294 44.6\uc5b5 \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \uc774\ub294 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 11.92%\ub97c \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uba74\uc5ed\uc694\ubc95\uc5d0 \ub300\ud55c \uaddc\uc81c \uc9c0\uc6d0 \uac15\ud654, HPV \uc591\uc131 \uad6c\uc778\ub450\uc554 \uc0ac\ub840 \uc99d\uac00, \uc815\ubc00 \uc885\uc591\ud559\uc758 \uc8fc\ub958\ud654 \ub4f1\uc774 \uc2dc\uc7a5 \uc131\uc7a5\uc758 \ud575\uc2ec \ub3d9\ub825\uc785\ub2c8\ub2e4. \ubd81\ubbf8\ub294 \uac00\uc7a5 \ud070 \uc2dc\uc7a5\uc774\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc2dc\uc7a5\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4. \uc2dc\uc7a5 \uc9d1\uc911\ub3c4\ub294 \uc911\uac04 \uc218\uc900\uc785\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \ubcf4\uace0\uc11c \uc694\uc57d<\/p>\n<p>*   \uc9c0\uc5ed\ubcc4: 2025\ub144 \ubd81\ubbf8\ub294 \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 41.88%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 2031\ub144\uae4c\uc9c0 14.05%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc785\ub2c8\ub2e4.<br \/>\n*   \uc57d\ubb3c \ub4f1\uae09\ubcc4: 2025\ub144 PD-1\/PD-L1 \uc5b5\uc81c\uc81c\uac00 38.52%\uc758 \ub9e4\ucd9c \uc810\uc720\uc728\uc744 \uae30\ub85d\ud588\uc73c\uba70, FGFR \uc5b5\uc81c\uc81c\ub294 2031\ub144\uae4c\uc9c0 13.34%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub978 \uc131\uc7a5\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<\/p>\n<p>*   \uce58\ub8cc \uc720\ud615\ubcc4: 2025\ub144 \uba74\uc5ed\uc694\ubc95\uc740 \uc2dc\uc7a5\uc5d0\uc11c \uc0c1\ub2f9\ud55c \ube44\uc911\uc744 \ucc28\uc9c0\ud588\uc73c\uba70, \ud45c\uc801 \uce58\ub8cc\ubc95 \ub610\ud55c \ub192\uc740 \uc131\uc7a5\ub960\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<br \/>\n*   \uc8fc\uc694 \uae30\uc5c5: \uc8fc\uc694 \uc2dc\uc7a5 \ucc38\uc5ec\uc790\ub85c\ub294 Merck &#038; Co., Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Sanofi \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub4e4 \uae30\uc5c5\uc740 \uc2e0\uc57d \uac1c\ubc1c \ubc0f \uc2dc\uc7a5 \ud655\uc7a5\uc744 \uc704\ud574 \ud65c\ubc1c\ud55c \uc5f0\uad6c \uac1c\ubc1c \ud65c\ub3d9\uc744 \ud3bc\uce58\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \uae30\ud68c<\/p>\n<p>\ub450\uacbd\ubd80\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 \ud601\uc2e0\uc801\uc778 \uce58\ub8cc\ubc95\uc758 \ub4f1\uc7a5\uacfc \uc9c4\ub2e8 \uae30\uc220\uc758 \ubc1c\uc804\uc73c\ub85c \uc9c0\uc18d\uc801\uc778 \uc131\uc7a5\uc744 \uacbd\ud5d8\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud2b9\ud788, \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c\uc640 \uac19\uc740 \uba74\uc5ed\uc694\ubc95\uc740 \uce58\ub8cc \ud328\ub7ec\ub2e4\uc784\uc744 \ubcc0\ud654\uc2dc\ud0a4\uba70 \ud658\uc790\ub4e4\uc5d0\uac8c \uc0c8\ub85c\uc6b4 \ud76c\ub9dd\uc744 \uc81c\uc2dc\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub610\ud55c, HPV \uad00\ub828 \ub450\uacbd\ubd80\uc554\uc758 \uc99d\uac00\uc640 \uc774\uc5d0 \ub300\ud55c \uc778\uc2dd \uc81c\uace0\ub294 \uc870\uae30 \uc9c4\ub2e8 \ubc0f \uce58\ub8cc \uc218\uc694\ub97c \ucd09\uc9c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc815\ubc00 \uc885\uc591\ud559\uc758 \ubc1c\uc804\uc740 \ud658\uc790 \ub9de\ucda4\ud615 \uce58\ub8cc\uc758 \uac00\ub2a5\uc131\uc744 \uc5f4\uc5b4\uc8fc\uba70, \uc774\ub294 \uc2dc\uc7a5\uc758 \uc911\uc694\ud55c \uc131\uc7a5 \ub3d9\ub825\uc73c\ub85c \uc791\uc6a9\ud560 \uac83\uc785\ub2c8\ub2e4.<\/p>\n<p>\ub3c4\uc804 \uacfc\uc81c<\/p>\n<p>\ub192\uc740 \uce58\ub8cc \ube44\uc6a9\uacfc \uc2e0\uc57d \uac1c\ubc1c\uc5d0 \ud544\uc694\ud55c \uc5c4\uaca9\ud55c \uaddc\uc81c \uc808\ucc28\ub294 \uc2dc\uc7a5 \uc131\uc7a5\uc5d0 \uc788\uc5b4 \uc8fc\uc694 \ub3c4\uc804 \uacfc\uc81c\ub85c \ub0a8\uc544 \uc788\uc2b5\ub2c8\ub2e4. \ub610\ud55c, \ud2b9\uc815 \uce58\ub8cc\ubc95\uc5d0 \ub300\ud55c \ub0b4\uc131 \ubc1c\ud604\uacfc \ubd80\uc791\uc6a9 \uad00\ub9ac \uc5ed\uc2dc \ud574\uacb0\ud574\uc57c \ud560 \uacfc\uc81c\uc785\ub2c8\ub2e4. \uc774\ub7ec\ud55c \ub3c4\uc804 \uacfc\uc81c\uc5d0\ub3c4 \ubd88\uad6c\ud558\uace0, \ubbf8\ucda9\uc871 \uc758\ub8cc \uc218\uc694\uac00 \ub192\uc740 \ub450\uacbd\ubd80\uc554 \ubd84\uc57c\uc5d0\uc11c \uc0c8\ub85c\uc6b4 \uce58\ub8cc \uc635\uc158\uc5d0 \ub300\ud55c \uc5f0\uad6c \uac1c\ubc1c\uc740 \uacc4\uc18d\ub420 \uac83\uc73c\ub85c \ubcf4\uc785\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \uc804 \uc138\uacc4 \ub450\uacbd\ubd80\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc5d0 \ub300\ud55c \ud3ec\uad04\uc801\uc778 \ubd84\uc11d\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \ub450\uacbd\ubd80\uc554\uc740 \uad6c\uac15, \ucf54, \ud6c4\ub450, \uc785\uc220, \ubd80\ube44\ub3d9 \ubc0f \uce68\uc0d8 \ub0b4\ubd80 \ub610\ub294 \uadfc\ucc98\uc5d0\uc11c \ubc1c\uc0dd\ud558\ub294 \ub2e4\uc591\ud55c \uc545\uc131 \uc885\uc591\uc744 \uc758\ubbf8\ud558\uba70, \ud654\ud559\uc694\ubc95, \uba74\uc5ed\uc694\ubc95, \ud45c\uc801\uc694\ubc95 \ub4f1 \ub2e4\uc591\ud55c \uc57d\ubb3c \ubc94\uc8fc\uac00 \ub2e8\ub3c5 \ub610\ub294 \ubcd1\uc6a9\uc73c\ub85c \uc0ac\uc6a9\ub420 \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \ubd84\uc11d\uc740 \uc57d\ubb3c \uc885\ub958(PD-1\/PD-L1 \uc5b5\uc81c\uc81c, EGFR \uc5b5\uc81c\uc81c, VEGF\/\ud608\uad00\uc2e0\uc0dd \uc5b5\uc81c\uc81c, \uba40\ud2f0\ud0a4\ub098\uc81c \uc5b5\uc81c\uc81c \ub4f1), \uc801\uc751\uc99d(\uad6c\uac15\uc554, \uad6c\uc778\ub450\uc554, \ube44\uc778\ub450\uc554, \ud6c4\ub450\uc554 \ubc0f \ud558\uc778\ub450\uc554, \uce68\uc0d8\uc554 \ub4f1), \ud22c\uc5ec \uacbd\ub85c(\uc815\ub9e5\uc8fc\uc0ac, \uacbd\uad6c \ub4f1), \ucd5c\uc885 \uc0ac\uc6a9\uc790(\ubcd1\uc6d0, \uc804\ubb38 \uc554 \uc13c\ud130, \uc18c\ub9e4 \ubc0f \uc628\ub77c\uc778 \uc57d\uad6d), \uadf8\ub9ac\uace0 \uc9c0\uc5ed(\ubd81\ubbf8, \uc720\ub7fd, \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591, \ub0a8\ubbf8, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74)\ubcc4\ub85c \uc138\ubd84\ud654\ub418\uc5b4 \uc788\uc2b5\ub2c8\ub2e4. \ud2b9\ud788 17\uac1c \uc8fc\uc694 \uad6d\uac00\uc5d0 \ub300\ud55c \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \ub3d9\ud5a5\uc744 USD \ubc31\ub9cc \ub2e8\uc704\ub85c \ucd94\uc815\ud558\uc5ec \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n<p>\ub450\uacbd\ubd80\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 \uc5f0\ud3c9\uade0 11.92%\uc758 \ub192\uc740 \uc131\uc7a5\ub960\uc744 \ubcf4\uc774\uba70, \uc8fc\uc694 \uc131\uc7a5 \ub3d9\ub825\uc740 \ub2e4\uc74c\uacfc \uac19\uc2b5\ub2c8\ub2e4. HPV \uc591\uc131 \uad6c\uc778\ub450\uc554 \ubc1c\ubcd1\ub960 \uc99d\uac00, 1\ucc28 \uce58\ub8cc\uc81c\ub85c\uc11c PD-1\/PD-L1 \uba74\uc5ed\uc694\ubc95\uc758 \ucc44\ud0dd \ud655\ub300, \ubcf4\ud5d8 \uc801\uc6a9 \ubc0f \uac00\uc774\ub4dc\ub77c\uc778 \ud3ec\ud568 \ubc94\uc704 \ud655\uc7a5, EGFR \ud45c\uc801 \ubcd1\uc6a9 \uc694\ubc95\uc758 \uc0ac\uc6a9 \uc99d\uac00 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4. \ub610\ud55c, AI \uae30\ubc18 \uc774\ube44\uc778\ud6c4\uacfc \uc601\uc0c1 \uc9c4\ub2e8 \uae30\uc220\uc744 \ud1b5\ud55c \uc870\uae30 \ubc1c\uacac\uacfc \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc758 \uc131\uc778 \ub0a8\uc131 HPV \ubc31\uc2e0 \uc811\uc885 \ud504\ub85c\uadf8\ub7a8 \ud655\uc0b0\ub3c4 \uc2dc\uc7a5 \uc131\uc7a5\uc5d0 \uae30\uc5ec\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. AI \uae30\ubc18 \ub525\ub7ec\ub2dd \uc774\ube44\uc778\ud6c4\uacfc \uc601\uc0c1 \uc2dc\uc2a4\ud15c\uc740 \ucd08\uae30 \uad6c\uac15 \ubcd1\ubcc0\uc5d0 \ub300\ud574 \ucd5c\ub300 100%\uc758 \uc9c4\ub2e8 \uc815\ud655\ub3c4\ub97c \ubcf4\uc5ec \uc870\uae30 \uac1c\uc785 \ubc0f \uc7a5\uae30\uc801 \uce58\ub8cc \uacb0\uacfc \uac1c\uc120\uc5d0 \uc911\uc694\ud55c \uc5ed\ud560\uc744 \ud569\ub2c8\ub2e4.<\/p>\n<p>\ubc18\uba74, \uc2dc\uc7a5\uc758 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\uc73c\ub85c\ub294 \uba74\uc5ed\ud56d\uc554\uc81c \ubc0f \ud45c\uc801 \uce58\ub8cc\uc81c\uc758 \ub192\uc740 \ube44\uc6a9, \uc2ec\uac01\ud55c \uce58\ub8cc \uad00\ub828 \ub3c5\uc131(3-4\ub4f1\uae09 \uba74\uc5ed \uad00\ub828 \uc774\uc0c1 \ubc18\uc751\uc774 \ud658\uc790\uc758 \ucd5c\ub300 1\/4\uc5d0 \uc601\ud5a5\uc744 \ubbf8\uccd0 \uc601\uad6c\uc801\uc778 \uce58\ub8cc \uc911\ub2e8\uc744 \ucd08\ub798\ud560 \uc218 \uc788\uc74c), \uc81c\ud55c\uc801\uc778 \ubc14\uc774\uc624\ub9c8\ucee4 \uac80\uc0ac \uc778\ud504\ub77c, \uadf8\ub9ac\uace0 \uc885\uc591 \uc720\uc804\uc801 \uc774\uc9c8\uc131\uc73c\ub85c \uc778\ud55c FGFR \uc5b5\uc81c\uc81c\uc758 \ube60\ub978 \ub0b4\uc131 \ubc1c\ud604 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4. FGFR \uc5b5\uc81c\uc81c\uc758 \uacbd\uc6b0, \uc885\uc591 \uc774\uc9c8\uc131\uc73c\ub85c \uc778\ud574 1\ub144 \uc774\ub0b4\uc5d0 \ud6a8\uacfc\uac00 \uac10\uc18c\ud558\ub294 \uacbd\ud5a5\uc774 \uc788\uc5b4 \uc9c0\uc18d\uc801\uc778 \ud6a8\uacfc\ub97c \uc704\ud55c \ubcd1\uc6a9 \uc694\ubc95 \uc5f0\uad6c\uac00 \ud544\uc694\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc9c0\uc5ed\ubcc4\ub85c\ub294 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc774 \ud604\uc7ac \uc2dc\uc7a5 \uc810\uc720\uc728\uc740 \ub0ae\uc9c0\ub9cc, \ube60\ub978 \uc758\ub8cc \ud22c\uc790, \ube44\uc778\ub450\uc554\uc758 \ud48d\ud1a0\ubcd1\uc801 \ud2b9\uc131, \uc815\ubd80 \uc9c0\uc6d0 HPV \ubc31\uc2e0 \uc811\uc885 \ud504\ub85c\uadf8\ub7a8 \ub4f1\uc5d0 \ud798\uc785\uc5b4 14.05%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\ub85c \ub2e4\ub978 \uc9c0\uc5ed\uc744 \ub2a5\uac00\ud558\ub294 \uc131\uc7a5\uc744 \ubcf4\uc774\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd \ubd84\uc11d\uc5d0\uc11c\ub294 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4, \uc2dc\uc7a5 \uc810\uc720\uc728, \uadf8\ub9ac\uace0 Merck, Bristol Myers Squibb, AstraZeneca, Roche, Pfizer \ub4f1 \uc8fc\uc694 \uae00\ub85c\ubc8c \uc81c\uc57d\uc0ac\ub97c \ud3ec\ud568\ud55c 20\uac1c \uae30\uc5c5\uc758 \ud504\ub85c\ud544(\uae00\ub85c\ubc8c \ubc0f \uc2dc\uc7a5 \uc218\uc900 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34 \uc815\ubcf4, \uc804\ub7b5 \uc815\ubcf4, \uc81c\ud488 \ubc0f \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \uc0ac\ud56d \ub4f1)\uc744 \ub2e4\ub8f9\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \ub610\ud55c \uc2dc\uc7a5 \uae30\ud68c\uc640 \ubbf8\ub798 \uc804\ub9dd, \ubbf8\ucda9\uc871 \uc218\uc694 \ud3c9\uac00 \ub4f1\uc744 \ud1b5\ud574 \uc2dc\uc7a5\uc758 \uc7a0\uc7ac\ub825\uc744 \uc2ec\uce35\uc801\uc73c\ub85c \ubd84\uc11d\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-43589","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/43589"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=43589"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/43589\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=43589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=43589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=43589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}